Though we have had vaccines against pertussis for
over seventy years now, we have been unable to control this common and
dangerous disease. In recent years, outbreaks of pertussis have occurred
in countries which have had high vaccination coverage for decades [1].
There could be several factors behind the current
resurgence of pertussis (Box I). Understanding these
factors will help in formulating strategies to protect children and
adults against this formidable disease.
BOX 1
Problems with Pertussis Immunization |
• The whole cell vaccine has significant adverse reactions,
which reduce the vaccination coverage significantly.
• Immunity induced by the acellular vaccine,
whole cell vaccine or the disease wanes over time.
• The acellular vaccines do not prevent
colonization and transmission of the organism, and the waning of
immunity is more rapid after them. These vaccines are several times
more expensive than the whole cell vaccines.
• The organism is evolving. It is altering or
omitting the antigens that are targeted by the vaccines (especially
pertussis toxin and pertactin, the important antigens of acellular
vaccines), producing more toxin to overcome the immune system, and
causing disease in spite of vaccination. These adapted strains can
be more virulent than the older strains.
• Infants are at particular risk of serious
disease. Most deaths caused by pertussis occur in children under six
months of age.
|
Waning of Pertussis Vaccine Immunity
Waning of immunity occurs with most vaccines, which
is the reason for booster doses. With some vaccines, the drop is small,
and the residual immunity is adequate to protect the vaccinee. However,
the waning of vaccine-acquired immunity to pertussis is a significant
problem, and leaves children, adolescents and adults unprotected. It
occurs with both types of vaccine, whole cell and acellular [2], with a
somewhat greater drop with the use of the acellular vaccines.
In Australia, during 2006-2012, acellular vaccines
(as opposed to whole cell vaccines) were used exclusively; the average
annual notification rate was more than 2.8 times that of the rate found
in 1995-2005 [3]. However, hospitalization and mortality rates remained
similar. South Australia introduced acellular vaccines into the primary
schedule two years earlier than in other jurisdictions. A peak in
pertussis notifications among those aged 5-9 and 10-12 years was
observed earlier than other provinces.
A study in USA, which shifted to all acellular
vaccine schedule in the nineties, found that pertussis immunity waned
significantly even after five doses [4]. Each year after the fifth dose
was associated with a 42% greater possibility of getting pertussis [4].
A meta-analysis of twelve trials found that each additional year after
the last dose had a 1.33 times increased incidence of pertussis [5].
Eight years after the last booster, only ten percent of vaccinees will
be protected. A study in Africa also found that risk of pertussis
increases with time elapsed since the booster dose of acellular vaccine
[6].
Historically, source of infection studies in infants
with pertussis have identified mothers as the most common source. In
recent years; however, this has changed, and fully vaccinated siblings
of age 2-3 years are more often the source. This has been found in
recent studies in both Australia [7] and in USA [8], which switched to
acellular vaccine in the 1990s. This suggests that vaccine-induced
immunity wanes rapidly before the second booster.
Similar studies from India are unavailable, because
the national immunization program only uses whole cell vaccines. The
proportion of children receiving acellular vaccine (from private
practitioners) is very small.
Adaptation by B. pertussis
Vaccines against B. pertussis have been used
for about seventy years now–enough time for the organism to learn ways
to circumvent human ingenuity. Studies in countries with high
vaccination coverage have shown that vaccination first reduced the
circulation of the organism, but adaptation allowed B. pertussis
to increase its circulation. These adaptations include changes in the
structure and quantity of important antigens like pertactin and
pertussis toxin. Increased production of pertussis toxin may suppress
the immune system [9].
Over the course of time, Darwinian selection caused
the replacement of the original B. pertussis types with types
that had modified versions of these important proteins [10]. In a study
in Europe, as many as 90% of B. pertussis strains isolated
between 1990 and 1996 had non-vaccine types of pertactin and pertussis
toxin. An increase in frequency of B. pertussis with non-vaccine
types of pertussis toxin is associated with an increase in pertussis
notifications. Similar findings have been reported from USA [11]. In
Australia, 30% of B. pertussis strains were found to be deficient
in pertactin [12].
Protecting the Infants
A distressing feature of the recent upturn in
pertussis incidence has been the high incidence of severe disease and
mortality in young infants. Young infants with the disease are prone to
complications like pneumonia, meningoencephalitis, and encephalopathy.
Various strategies are being tried to protect
infants. These include immunizing the mother during pregnancy to provide
transplacental transfer of immunity, vaccinating newborns, and a cocoon
strategy that involves vaccinating everyone around the infant.
Maternal Vaccination
One recent study found that only 37% of pregnant
women had anti-pertussis antibodies. After a dose of Tdap, this figure
rose to 90% [13], and almost 95% of newborns were born with antibodies.
Presumed protective levels were maintained in 66% babies at age 2
months. Vaccinating pregnant women appears to be an effective and safe
intervention for protecting young infants [14,15].
Pertussis antibodies reach a peak 2 weeks after
vaccination, and decline thereafter. Women vaccinated with Tdap early in
pregnancy do not transfer adequate levels of pertussis antibodies to
their babies [16]. Vaccination in the third trimester (at 27-36 weeks)
is recommended. This will optimize antibody transfer, which mainly
occurs between weeks 36-40 of gestation, and provide protection to the
baby till the primary DTP series is given and takes effect. Maternal
vaccination was seen to protect babies against pertussis [17] in the UK,
where vaccine coverage among pregnant women was 64%.
However, this approach is not perfect. Premature
babies will receive very little placental transfer. It is not known what
effect the transplacentally acquired antibodies will have on the
development of immunity in response to the primary DTP series.
Cocoon Strategy
This consists of vaccinating all adult and adolescent
family members when a baby is born. There is some evidence of prevention
of transmission of pertussis to the baby [18]. However, this strategy is
difficult to implement, and may not be effective by itself [19].
Besides, immunity takes two weeks to develop after vaccination, during
which time an adult may transmit the disease. Siblings, who are not
considered for vaccination in the cocooning strategy, may also transmit
the infection.
Adults and adolescents can only be immunized with the
acellular vaccines. The cost of such a strategy, and the availability of
the vaccines, also become limiting factors in developing countries.
Newborn Vaccination
It’s not a new idea – it was first tried fifty years
ago [20]. More recently, acellular pertussis vaccines have been tried at
birth [21]. They are well tolerated and produce low levels of pertussis
antibodies, which are probably not fully protective. However, they act
as efficient priming, and the first 1-2 doses of the regularly scheduled
vaccine elicit good levels of antibodies. Unfortunately, by the age of
twelve to eighteen months, antibody levels are low, a phenomenon called
immune tolerance or blunting. Newborn vaccination is possible, and
needed, but the currently available vaccines are not appropriate.
Newer Vaccines
The currently used vaccines have been seen to be
poorly protective in the long term, unable to protect young infants, and
requiring repeated doses to maintain some protection. Better vaccines
are needed, and several approaches are being tried. Acellular vaccines
contain some or all of the following five antigens: detoxified pertussis
toxin, pertactin, fimbrial hemaglutinin, fimbriae type 2 and fimbriae
type 3. Bordetella pertussis are evading the vaccine protection
by eliminating some antigens. Newer antigens being tried out in vaccines
are BrkA, adenylate cyclase, and IRP1-3. These antigens are almost
always present in Bordetella pertussis isolates, even those in
which pertussis toxin and/or pertactin are absent. The protective effect
of these is being investigated.
Adjuvants are significant. The traditional alum
adjuvants encourage production of antibodies (Th2 response). However, it
is known that Th1 response and cell mediated immunity is a vital
component of pertussis protection. Adjuvants that provoke a Th1 type
response are being investigated.
A live attenuated vaccine (BPZE-1) has been developed
by eliminating three important molecules from B. pertussis -
pertussis toxin, dermonecrotic toxin, and tracheal cytotoxin. This
strain is non-toxic but immunogenic. It has been tried and found to be
safe and effective in adolescents and adults [22], with protective
efficacy against B. parapertussis also. The immunity is likely to
be long-lasting.
Another advantage is that these vaccines can be given
nasally, thus eliminating the pain of the injection and associated local
side effects. Once safety and immunogenicity are well proven, this
vaccine can be used in newborns to provide immunity early in life. It
will probably be many years before this vaccine is available and
licensed for clinical use.
Whole cell vaccines have a large number of antigens,
which make them effective against adapted B. pertussis also.
These vaccines also generate a robust Th17/Th1 response, and lead to the
development and persistence of memory T and B cells. Currently the
challenge is to reduce the reactogenicity and unpleasant side effects of
whole cell vaccines while keeping their efficacy intact. One approach is
to remove the lipopolysaccharide from the killed vaccine preparation,
since this component is believed to be responsible for most of the
adverse effects.
The cost-effectiveness, prevention of colonization
and transmission, and better long term protection of whole cell vaccines
makes this approach attractive. Improved acellular vaccines with more
purified molecules are likely to be expensive.
Optimizing the Schedule for Available Vaccines
The usual five dose schedule consists of three doses
in the first year, and boosters in the second year and at 4-6 years age.
The first year doses should be started after the age of six weeks, and
should be separated by at least four weeks each. As we know, longer
intervals (for example, six or eight weeks) are better for generating a
stronger immune response. On the other hand, the young infants may
remain vulnerable for a significant period. These decisions need to be
made locally, considering the pattern and incidence of disease.
Completion of the schedule is of prime importance.
Factors associated with getting pertussis are missing
a dose, the second booster at four years instead of five years, and an
interval of less than 36 months between dose four and dose five [23].
Using whole cell vaccines for the priming doses (in the first year) is
associated with better long term protection [24]. The boosters can be
either whole cell or acellular vaccine. The booster doses increase
antibody levels and provide long term protection.
Children who have received these doses, can be given
a dose of Tdap after age 10 years to boost the immunity. Only a single
dose of Tdap is recommended currently, since pertussis vaccine is always
in combination with diphtheria and tetanus toxoids, which are harmful if
too many doses are given. The availability of solo pertussis vaccines
would allow vaccination of newborns, as well as more frequent boosters
for adolescents and adults.
Epilogue
For those of us struggling to provide and plan good
healthcare for children in resource-limited settings, there are several
challenges. Many of the problems do not have easy solutions, and the
solutions of the western world may not be appropriate for us.
The current vaccines used for protection against
pertussis all suffer from waning of immunity. Adolescents and adults are
almost unprotected, and pertussis in this age group is a risk for
community spread. Disseminating the knowledge about the clinical
features of whooping cough in these age groups can lead to earlier
diagnosis and lesser spread. The organism has evolved, reducing the
effectiveness of some currently used vaccines. New (better) vaccines
need large investments of time and money to formulate and test them.
There are vaccines in the pipeline, but it will be many years before
they get to clinical use. Even when they do become available, they are
likely to be too expensive for use in the national immunization programs
of developing countries.
Optimal use of currently available vaccines can
provide good protection to children and adolescents. This includes
appropriate intervals between currently recommended doses, choosing the
most effective vaccines available, and increasing the number and
coverage of booster doses.
Newer is not always better. It is now accepted that
acellular pertussis vaccines have lower initial efficacy, faster waning
of immunity, and possibly a reduced impact on transmission relative to
currently internationally available whole cell vaccines [25]. Though
acellular vaccines have lesser minor side effects, they have slightly
lower efficacy, equivalent frequency of serious adverse events and far
greater cost [26].
The USA and other western countries found out about
the poor protection with acellular pertussis vaccine when it was too
late for them to go back. Countries where the whole cell vaccine is
still in use are more fortunate in having both options to decide from.
The use of acellular vaccines to control pertussis requires high primary
coverage and multiple booster doses. Countries that cannot afford this
are better served by the whole cell vaccines. In our own country, these
vaccines have been found to be safe and well-tolerated [27].
Infants can be protected early by using innovative
strategies like maternal vaccination in pregnancy, newborn vaccination,
and cocooning. The Federation of Obstetrics and Gynaecological Societies
of India has accepted the IAP’s recommendation to use dT in pregnancy
some years ago. Changing to Tdap will be more challenging because of the
significantly greater cost involved. The cost issue will also come in
the way of implementing the cocooning strategy, which will mostly need
Tdap use in older children and adults. As we all know, medicine and
science can only do so much; political will and the appropriate shifting
of priorities are equally important for good healthcare.
1. World Health Organization. Revised guidance on the
choice of pertussis vaccines: July 2014. Wkly Epidemiological
Rec.2014;89:337-44.
2. Crespo I, Broner S, Soldevila N, Martínez A,
Godoyac P, Sala-Farré M, et al. Characteristics of pertussis
outbreaks in Catalonia, Spain, 1997 to 2010. Human Vaccines and
Immunotherapeutics. 2015;11: 231-5.
3. Pillsbury A , Quinn HE, McIntyre PB . Australian
vaccine preventable disease epidemiological review series: pertussis,
2006-2012. Commun Dis Intell Q Rep. 2014;38:E179-94.
4. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B,
Baxter R. Waning protection after fifth dose of acellular pertussis
vaccine in children. N Engl J Med. 2012;367:1012-9.
5. Ashleigh McGirr, David N. Fisman. Duration of
pertussis immunity after dtap immunization: A meta-analysis. Pediatrics.
2015;135:331-43.
6. Lacombe K, Yam A, Simondon K, Pinchinat S,
Simondon F. Risk factors for acellular and whole-cell pertussis vaccine
failure in Senegalese children. Vaccine. 2004;23:623-8.
7. Bertilone C, Wallace T, Selvey LA. Finding the
‘who’ in whooping cough: Vaccinated siblings are important pertussis
sources in infants 6 months of age and under. Commun Dis Intell Q Rep.
2014;38:E195-200.
8. Skoff TH, Kenyon C, Cocoros N, Liko J, Miller L,
Kudish K, et al. Sources of infant pertussis infection in the
United States. Pediatrics. 2015;136:635-41.
9. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis
resurgence: waning immunity and pathogen adaptation - two sides of the
same coin. Epidemiol Infect. 2014;142:685-94.
10. Mooi FR, van Loo IHM, King A. Adaptation of
Bordetelle pertussis to vaccination: A cause for it reemergence?
Emerg Infect Dis. 2001;7:526-8.
11. Cassiday P, Sanden G, Heuvelman K, Mooi FR,
Bisgard KM, Popovic T. Polymorphism in Bordetella pertussis
pertactin and pertussis toxin virulence factors in the United States,
1935-1999. J Infect Dis. 2000;12:1402-8.
12. Lam C, Octavia S, Ricafort L, Sintchenko V,
Gilbert GL, Wood N, et al. Rapid increase in pertactin-deficient
Bordetella pertussis isolates, Australia. Emerg Infect Dis.
2014;20:626-33.
13. Vilajeliu A, Goncé A, López M, Costa J, Rocamora
L, Ríos J, et al. Combined tetanus-diphtheria and pertussis
vaccine during pregnancy: transfer of maternal pertussis antibodies to
the newborn. Vaccine. 2015;33:1056-62.
14. Dabrera G, Amirthalingam G, Andrews N, Campbell
H, Ribeiro S, Kara E, et al. A case-control study to estimate the
effectiveness of maternal pertussis vaccination in protecting newborn
infants in England and Wales, 2012-2013. Clin Infect Dis. 2015;60:333-7.
15. Kharbanda EO, Vazquez-Benitez G, Lipkind HS,
Klein NP, Cheetham TC, Naleway A, et al. Evaluation of the
association of maternal pertussis vaccination with obstetric events and
birth outcomes. JAMA. 2014;312:1897-904.
16. Healy CM, Rench MA, Baker CJ. Importance of
timing of maternal combined tetanus, diphtheria, and acellular pertussis
(Tdap) immunization and protection of young infants. Clin Infect Dis.
2013;56:539-44.
17. Amirthalingam G, Andrews N, Campbell H, Ribeiro
S, Kara E, Donegan K, et al. Effectiveness of maternal pertussis
vaccination in England: an observational study. Lancet. 2014;384:1521-8.
18. Quinn HE, Snelling TL, Habig A, Chiu C, Spokes
PJ, and McIntyre PB. Parental Tdap boosters and infant pertussis: a
case-control study. Pediatrics 2014;134:713-20.
19. Healy CM, Rench MA, Wootton SH, Castagnini LA.
Evaluation of the impact of a pertussis cocooning program on infant
pertussis infection. Pediatr Infect Dis J. 2015;34:22-6.
20. Provenzano RW, Wetterlow LH and Sullivan CL.
Immunization and antibody response in the newborn infant, I. pertussis
inoculation within twenty-four hours of birth. N Engl J Med.
1965;273:959-65.
21. Belloni C, De Silvestri A, Tinelli C, Avanzini
MA, Marconi M, Strano F, et al. Immunogenicity of a
three-component acellular pertussis vaccine administered at birth.
Pediatrics. 2003;111:1042-5.
22. Jahnmatz M, Amu S, Ljungman M, Wehlin L, Chiodi
F, Mielcarek N, et al. B-cell responses after intranasal
vaccination with the novel attenuated Bordetella pertussis vaccine
strain BPZE1 in a randomized phase I clinical trial. Vaccine.
2014;32:3350-6.
23. Khan FN, Lin M, Hinkle CJ, Franklin P, Luther R,
Woodruff F, et al. Case-control study of vaccination history in
relation to pertussis risk during an outbreak among school students.
Pediatr Infect Dis J. 2006;25: 1132-6.
24. Liko J, Robison SG, Cieslak PR. Priming with
whole-cell versus acellular pertussis vaccine. N Engl J Med.
2013;368:581-2.
25. World Health Organization. Meeting of the
Strategic Advisory Group of Experts on Immunization, April 2014 –
conclusions and recommendations. Wkly Epidemiological Rec.
2014;89:221-36.
26. Mathew JL. Acellular pertussis vaccines:
Pertinent issues. Indian Pediatr. 2008;45:727-9.
27. Bavdekar SB, Maiya PP, Subba Rao SD, Datta SK,
Bock HL. Immunogenicity and safety of combined diphtheria-tetanus-whole
cell pertussis-hepatitis B/ haemophilus influenzae type b vaccine in
Indian infants. Indian Pediatr. 2007;44:505-10.